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Abstract 27 
 28 
Background: Many people with Multiple Sclerosis experience problems with 29 
walking, which can make daily activities difficult and often leads to falls. Foot 30 
sensation plays an important role in keeping the body balanced whilst walking 31 
however, people with Multiple Sclerosis often have poor sensation on the soles of 32 
their feet. Wearing a specially designed shoe insole, which enhances plantar 33 
sensory information, could help people with Multiple Sclerosis to walk better. This 34 
study will explore whether long-term wear of a textured insole can improve walking in 35 
people with Multiple Sclerosis.  36 
Methods: A prospective randomised controlled trial with two parallel groups will be 37 
conducted aiming to recruit 176 people with Multiple Sclerosis living in the 38 
community (Brisbane, Australia). Adults with a clinical diagnosis of Multiple 39 
Sclerosis, Disease Steps score 1-4, who are ambulant over 100m and who meet 40 
specific inclusion criteria will be recruited. Participants will be randomised to a 41 
smooth control insole (N=88) or textured insole (N=88) group. The allocated insole 42 
will be worn for 12-weeks within participants’ own footwear, with self-report wear 43 
diaries and falls calendars being completed over this period. Blinded assessors will 44 
conduct two baseline assessments and one post-intervention assessment. Gait 45 
tasks will be completed barefoot, wearing standardised footwear only, and wearing 46 
standardised footwear with smooth and textured insoles. The primary outcome 47 
measure will be mediolateral base of support when walking over even and uneven 48 
surfaces. Secondary measures include: spatiotemporal gait parameters (stride 49 
length, stride time variability, double-limb support time, velocity), gait kinematics (hip, 50 
knee, ankle joint angles; toe clearance; trunk inclination; arm swing; mediolateral 51 
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pelvis/head displacement), foot sensation (light touch-pressure, vibration, two-point 52 
discrimination) and proprioception (ankle joint position sense). Group allocation will 53 
be concealed and all analyses based on an intention to treat principle. 54 
Discussion: This study will explore the effects of wearing textured insoles over 12-55 
weeks on gait, foot sensation and proprioception in people with Multiple Sclerosis. 56 
The study has the potential to identify a new, evidence-based footwear intervention 57 
which has the capacity to enhance mobility and independent living in people with 58 
Multiple Sclerosis. 59 
Trial registration: Australian New Zealand Clinical Trials Registry 60 
ACTRN12615000421538. Registered 4 May 2015. 61 
 62 
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 64 
 65 
 66 
 67 
 68 
 69 
 70 
 71 
 72 
 73 
 74 
 75 
 76 
4 
 
Background 77 
Falls are a major threat to the health and well-being of people with Multiple Sclerosis 78 
(pwMS)[1, 2]. Up to 50% of pwMS report falling within the past 6 months, and 50% of 79 
these falls result in injuries [3]. Impaired mobility and balance are two major risk 80 
factors for falls in people with pwMS [2]. In one study 85% of pwMS report gait 81 
disturbances as their main complaint [4], and continued loss of mobility amongst 82 
their greatest concerns for the future [5]. Impaired walking in pwMS is typically 83 
characterised by an increased mediolateral (ML) base of support, reduced stride 84 
length, step length and velocity, and prolonged double-limb support time during level 85 
ground walking, relative to healthy individuals [6-8]. Incipient signs of deteriorating 86 
walking ability can even be observed in the early stages of the disease [6-8]. 87 
Therefore, interventions that effectively preserve or enhance walking capacity are 88 
paramount to improving quality of life and maintaining independence. 89 
 90 
Current rehabilitation strategies to improve gait and balance in pwMS, predominantly 91 
involve exercise participation to address deficient motor function, with some 92 
consideration given to sensory training [9-13]. These multimodal approaches have 93 
been shown to significantly improve several clinical and functional measures in 94 
pwMS, including dynamic balance, rate of falls, physical activity levels, perceived 95 
balance confidence, walking ability, and quality of life [9-13]. However, there is an 96 
urgent need to develop additional methods to complement exercise, which target MS 97 
sensory impairments [14-19] to a greater extent, in particular tactile sensation and 98 
proprioception, in order to preserve and enhance mobility for as long as possible. 99 
Previous evidence has shown that a strong relationship exists between foot 100 
sensation and standing balance performance in pwMS [15]. Similarly, a loss of lower 101 
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limb proprioception, including joint position sense at the ankles and feet in pwMS can 102 
detrimentally affect gait and standing balance, leading to greater dependence on 103 
compensatory motor mechanisms in order to remain upright [17, 19]. An increasing 104 
body of literature suggests footwear interventions may be another treatment option 105 
to help improve gait performance in pwMS [20-22].  106 
 107 
Textured shoe insoles, designed to enhance plantar sensory information, have been 108 
shown to consistently alter gait patterns in the short-term, potentially improving 109 
walking stability in a range of clinical populations including older fallers [23], adults 110 
with Parkinson’s disease [24] and pwMS [20, 21]. To date, exploratory studies 111 
indicate that textured insoles can lead to beneficial alterations in spatiotemporal gait 112 
parameters such as a reduced ML base of support [20], improved gait kinetics, and 113 
kinematics [21] in pwMS. Significant increases in lower limb muscle activity during 114 
both stance and swing phases of gait, changes in knee and hip excursion and 115 
ground reaction forces, have been found immediately after pwMS wore textured 116 
insoles, with these changes attributed to enhanced stimulation of plantar 117 
mechanoreceptors [21]. Furthermore, after wearing textured insoles for two weeks, 118 
significant increases have been also observed in stride and step length, and 119 
significant decreases in the size of the ML base of support during level-ground 120 
walking: interpreted to represent a more confident gait pattern. These changes were 121 
observed independent of wearing the textured insoles, again supporting the theory 122 
that a sensory training effect may have occurred during the intervention period [20]. 123 
However, recent evidence reports no significant changes either in spatiotemporal 124 
gait measures during treadmill walking or plantar sensitivity after wearing textured 125 
insoles over a longer, 4-week intervention period in pwMS [25]. It is possible that any 126 
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effects of textured insoles on gait may only be identified when walking in conditions 127 
that emulate everyday life [25]. Further, whilst no changes were observed in plantar 128 
sensitivity, alterations may have occurred in other measures of sensory function, 129 
such as foot proprioception [25]. As such, the short-term effects of textured insoles 130 
on mobility, and their proposed underlying mechanisms in pwMS, remain unclear. It 131 
is possible that the benefits of textured insoles in pwMS may accrue, and additional 132 
benefits may be observed, with prolonged wear over 4-weeks, but this has not yet 133 
been explored. Previous work has shown limited effects of textured insoles on gait 134 
and balance measures in pwMS immediately after wearing the insoles for the first 135 
time, with subsequent improvements observed following 2-weeks wear [20].  136 
 137 
This randomised controlled trial will determine whether wearing textured shoe 138 
insoles for 12-weeks can improve gait when walking over even and uneven surfaces, 139 
in  pwMS. The primary aim of this study is to explore whether prolonged wear of 140 
textured insoles alters ML base of support (as a measure of walking stability) from 141 
baseline assessment 2 to the post-intervention assessment. Secondary aims are to 142 
explore whether prolonged wear of textured insoles alters other spatiotemporal gait 143 
parameters including stride length, stride time variability, double-limb support time, 144 
and gait velocity; gait kinematics (specifically lower limb joint and trunk movement) 145 
and; changes in the perception of foot sensation or proprioception, as underlying 146 
mechanisms associated with improvements in spatiotemporal gait parameters.  147 
 148 
Methods 149 
Design 150 
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A prospective, parallel group, single blinded, randomised controlled trial with 176 151 
pwMS living in the community will be conducted, conforming to the Consolidated 152 
Standards of Reporting Trials guidelines [26] (Figure 1). 153 
 154 
Sample size 155 
Sample size has been calculated for the primary outcome measure, ML base of 156 
support during even surface walking, based on our pilot data [20]. Our preliminary 157 
study reported mean (SD) readings at baseline for base of support of 13.78 (5.11) 158 
cm and a significant mean change of -1.66 cm (P=0.02) at 2-weeks post. With a 159 
power of 80%, and alpha level of 0.05, a calculation for two related groups indicated 160 
that n=76 were required in each group. In our pilot study we recruited 46 pwMS, with 161 
no loss to follow-up across two visits (although completion of all test procedures was 162 
limited by fatigue in some participants). As this randomised controlled trial involves a 163 
longer intervention period, we will allow for a 15% attrition rate. An 85% retention 164 
rate over a 16-week period (Baseline assessments at Week 0 and Week 4, 165 
intervention 12-weeks, Post-intervention assessment at Week 16) is appropriate 166 
based on previous MS intervention studies. Three randomised controlled trials with 167 
12-week intervention periods conducted in pwMS, report retention rates of 82% [27], 168 
88% [11], and 90% [28]. Therefore, 88 participants per group will be recruited, giving 169 
a total of 176 participants.  170 
 171 
Location and setting 172 
All assessments will be conducted in the Gait Laboratory within the Institute of 173 
Health and Biomedical Innovation at Queensland University of Technology, 174 
Brisbane, Australia. 175 
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 176 
Participants 177 
Men and women with a diagnosis of MS will be identified through a pool of sampling 178 
frames including MS Queensland, local MS health care providers and community 179 
organisations across the Brisbane, Gold Coast, and Logan regions, Australia. 180 
Participants will be recruited through mainstream media advertisements and written 181 
materials distributed to individuals listed on the MS Queensland database and those 182 
attending local MS Clinics. Recruitment procedures will be centrally coordinated by 183 
clinical staff working within each organisation to maintain patient confidentiality. 184 
Participants will be invited to voluntarily contact the Principal Investigator for further 185 
information. Participants will be eligible to take part if they meet the following criteria: 186 
aged over 18 years; clinical diagnosis of MS; ambulant over 100 metres with or 187 
without the use of an assistive device; and Disease Step rating of 1-4 [29]. 188 
Participants rated as Disease Step 1 (Mild disability: Mild symptoms and/or signs) to 189 
4 (Late cane: Unable to walk 25 feet without a cane/unilateral support) will be eligible 190 
to take part in this study, ensuring they have sufficient ambulatory capacity to 191 
complete the gait trials. Exclusion criteria are: neurological conditions other than MS; 192 
peripheral neuropathy; currently being prescribed over-the-counter or custom-made 193 
foot orthoses; cardiovascular or orthopaedic conditions including recent injury to the 194 
back or legs limiting ambulation; unstable psychiatric condition or cognitive 195 
impairment (Short Form Mini-Mental State Examination [MMSE] score <24) [30]. 196 
Furthermore, enrolled participants who report an exacerbation of MS symptoms 197 
persisting >24hrs, four weeks prior to, or at any time during, the intervention period 198 
will also be excluded from the study. All participants will initially be screened via 199 
telephone interview, and invited to attend a clinical examination, to confirm eligibility. 200 
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Written informed consent will be obtained from all participants. This study was 201 
approved by the Medical Research Ethics Committee at The University of 202 
Queensland (#2014000781) and University Human Research Ethics Committee at 203 
Queensland University of Technology (#1500000615).  204 
 205 
Randomisation and blinding 206 
The concealed randomisation schedule will be established using a computer 207 
generated random number sequence, and maintained by an offsite investigator who 208 
is neither involved with the enrolment nor assessment of participants. Consecutively 209 
numbered, randomly ordered, opaque envelopes containing group allocation (in a 210 
1:1 ratio), will be opened consecutively after baseline assessment 2, by a second 211 
research assistant who is only responsible for administering the insoles. All 212 
investigators and the first research assistant, who are involved in the enrolment or 213 
assessment of participants over the duration of the trial, will remain blinded to group 214 
allocation. Following baseline assessment 2, the Principal Investigator and first 215 
research assistant will leave the gait laboratory to ensure blinding to the insole 216 
condition. The second research assistant will then fit the participant with their 217 
allocated insole, and provide advice regarding; frequency of wear, completion of 218 
insole wear diaries, and emergency contact details for local podiatry care. 219 
Participants will be instructed not to divulge their group allocation. As it is not 220 
possible for participants to be blinded to their allocated group (those in the 221 
intervention group will be able to perceive the textured material against the sole of 222 
their foot), the full aims of the study will be concealed. Participants will not be told 223 
that the intervention is designed to provide enhanced plantar sensory information 224 
which could potentially lead to changes in gait. Such knowledge could influence how 225 
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participants walk and they could purposefully alter their walking patterns between-226 
conditions: debriefing will occur upon completion of the study. Furthermore, coding of 227 
participants will not refer to group. 228 
 229 
Intervention 230 
In this randomised controlled trial we will investigate two different shoe insoles: 231 
textured insoles and smooth (control) insoles. Both insoles have been implemented 232 
in previous research strategies in pwMS [20], older fallers [23], and middle-aged 233 
adults [31]. The textured insole (Evalite Pyramid ethyl vinyl acetate [EVA], 3mm 234 
thickness, shore value A50, black, OG1549; Algeos PTY Ltd., Liverpool, UK) was 235 
selected from a range of EVA soling materials, and has small, pyramidal peaks with 236 
centre-to-centre distances of approximately 2.5mm. The smooth control insole 237 
(Medium Density EVA, 3mm thickness, shore value A50, black, OG1304; Algeos 238 
PTY Ltd., Liverpool, UK) was chosen from a range of plain EVA materials and has a 239 
flat surface with no indentations. Insoles will be tailored to each participant’s shoe 240 
size. An experienced podiatrist will oversee and advise on the delivery of insoles, 241 
and any podiatry-related issues including insole fit, durability, and dermatological or 242 
peripheral changes at the foot during the intervention period. Participants will be 243 
instructed to wear their allocated insoles, in their own shoes, as much as possible. 244 
All assessments of balance and gait will be conducted with the participants wearing 245 
standardised footwear (Donated by Pacific Brands Australia Pty Ltd), comprising a 246 
basic construct rubber-soled shankless shoe with a soft canvas upper [32], into 247 
which the insoles will be inserted. This standardisation will control for any possible 248 
insole/shoe interactions across participants, which could impact the findings. To 249 
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allow for familiarisation to the footwear, participants will be instructed to walk for 5 250 
minutes in the standardised shoes prior to testing. 251 
 252 
Primary outcome measures 253 
Spatiotemporal gait variables: The primary gait measure will be ML base of support, 254 
when walking over an even and uneven surface. Our pilot study demonstrated that 255 
after 2-weeks wear of the textured insoles, the significant mean reduction in base of 256 
support was 1.7cm (P=0.02) compared to baseline measures [20]. The magnitude of 257 
this effect is highly clinically relevant as previous research indicates a mean 258 
difference of ~2cm in base of support exists between pwMS and healthy controls [6, 259 
7]. This suggests that the textured effect is clinically significant, and may be of 260 
sufficient magnitude to reduce base of support to a level similar to healthy adults.  261 
 262 
Secondary outcome measures 263 
Spatiotemporal gait variables: Additional measures of walking stability will include 264 
stride length, stride time variability, double-limb support time, and gait velocity, when 265 
walking over an even and uneven surface. Our pilot study reported that wearing 266 
textured insoles for 2-weeks led to significant increases in mean stride length (Right 267 
leg: 5.8cm [P<0.01]; Left leg: 4.4cm [P<0.01]), compared to baseline assessment 268 
[20]. Details of specific methods underpinning all measures are provided in the 269 
assessment section below. 270 
 271 
Gait kinematics: During both even and uneven surface walking trials, lower limb gait 272 
kinematics will be collected using a 3D motion capture system and will include hip, 273 
knee, ankle joint angles (and their inter-relationships), and foot-to-floor angle to 274 
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determine maximum toe clearance. Segmental measures of trunk inclination, as well 275 
as arm swing, mediolateral pelvis and head displacement will also be collected. 276 
Specific details are presented below.  277 
 278 
Sensory measures: Light touch-pressure sensation will be determined by recording 279 
the smallest monofilament that the participant can perceive at five locations on the 280 
foot as detailed below [15]. Vibration sense will be measured using a digital stop 281 
watch, started when the tuning fork touches the participant’s skin at two sites on the 282 
feet, then stopped when the participant indicates the vibration can no longer be felt. 283 
The average of three trials will be recorded for both feet (seconds) [15]. For two-point 284 
discrimination, when the participant perceives two stimuli as one, the distance will be 285 
recorded in mm [15]. Ankle joint position sense will be determined by the participant 286 
performing the ankle joint position sense test [33].  287 
 288 
Insole wear and falls: Participants will be followed for 12-weeks with insole wear self-289 
reported diaries and falls calendars to determine: i) number of hours insoles are 290 
worn and ii) frequency, time, location of any falls and injuries. In this study, a fall will 291 
be defined as an unexpected event in which the participant comes to rest on the 292 
ground, floor or lower level [34].   293 
 294 
Clinical screening examination 295 
Prior to enrolment, all individuals will undergo a clinical screening examination, 296 
conducted by a Specialist Neurological Physiotherapist (KW), which will include the 297 
assessment of disease stage, and symptoms including spasticity and ataxia. Stage 298 
of disease will be determined using Disease Steps [29]. This tool is an assessment 299 
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of disability in patients with MS, which has low inter-rater variability, correlates 300 
strongly to the Expanded Disability Severity Scale at initial assessment (EDSS), and 301 
can be used to monitor disease progression [35]. Spasticity will be assessed using 302 
the Tardieu Scale [36], and ataxia scored using the Brief Ataxia Rating Scale [37].  303 
 304 
Baseline assessments 305 
Demographics including gender, age, height, and body mass will be collected. To 306 
characterise the study sample, participants will be asked to complete questionnaires 307 
that address relevant medical history and medications, length of time since diagnosis 308 
of MS, current MS symptoms using the MS Impact Scale (MSIS-29) [38], and 309 
perceived walking ability using the MS Walking Scale (MSWS-12) [39]. Quality of life, 310 
the impact of fatigue and pain, and perceived disability will be assessed using four 311 
self-report questionnaires: MS Quality of Life Instrument (MS QoL-54) [40]; Modified 312 
Fatigue Impact Scale (a questionnaire which measures how MS-related fatigue 313 
affects everyday life including physical, cognitive and psychosocial functioning [41]); 314 
Medical Outcomes Study (MOS) Pain Effects Scale (a MS-specific questionnaire 315 
which assesses how pain and disturbing sensations, such as burning or tingling, 316 
affect everyday life [42]); and the Perceived Deficits Questionnaire (a MS-specific 317 
questionnaire which assesses several domains of cognitive function that are 318 
commonly affected by MS: attention; retrospective memory, prospective memory, 319 
planning and organization [43]). Number of self-reported falls experienced in the 320 
previous 12 months will be recorded, and current fear of falling assessed using the 321 
Falls Efficacy Scale-International [44].  322 
 323 
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Following the clinical screening examination, all participants will complete initial 324 
assessments of gait, foot sensation and proprioception (Baseline assessment 1). 325 
Standing balance and activity levels will also be measured at baseline assessment 1 326 
only. Each participant will receive a wireless activity monitor (activPAL, Glasgow, 327 
Scotland), to be worn every day for seven consecutive days; allowing us to 328 
characterise the activity of the study group, monitor habitual weekly activity levels 329 
and establish any relationships with gait performance at baseline. The increasing 330 
use of accelerometry in pwMS [45, 46] is accredited to its ability to allow monitoring 331 
of changes in walking impairments with disease progression (e.g. worsening of MS) 332 
or disease activity (e.g. acute relapse), over long periods of time [47]. Four weeks 333 
after baseline assessment 1, a second baseline assessment (Baseline assessment 334 
2) will be conducted. The purpose of this 4-week waiting period is to establish each 335 
participant’s natural rate of MS disease progression, specifically the magnitude of 336 
change in the primary and secondary outcomes measures of gait, foot sensation and 337 
proprioception, prior to delivery of the intervention. 338 
 339 
Gait 340 
Gait performance will be evaluated by completing a 12m walk over an even surface 341 
and an uneven surface. The even surface will consist of a level, vinyl material: the 342 
top cover of an instrumented walkway (GAITRite®, CIR Systems, Inc., Havertown, 343 
PA 19083, USA). The GAITRite® system is an electronic walkway, approximately 344 
8.2m long (the active area being 0.61m wide and 7.32m long), which has been 345 
shown to have high reliability [48, 49]. The uneven surface (placed directly on the 346 
laboratory floor, adjacent to the GAITRite® walkway) will consist of two layers of 347 
thick soft foam, over which small blocks of wood of uneven shapes and sizes will be 348 
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spread in a random manner; with a top layer of artificial grass covering the walkway, 349 
using previously described methods [50]. Maintenance of stability when walking 350 
requires individuals to control their centre of mass within a constantly changing base 351 
of support: this becomes even more challenging when the surface is uneven, 352 
increasing the risk of loss of balance, resulting in a fall. Deficits in balance control 353 
during walking, or conversely the therapeutic benefit of interventions (such as shoe 354 
insoles) on walking performance may only become apparent when the balance 355 
challenge is sufficiently demanding. The uneven walking surface will emulate a 356 
situation encountered in daily life. A start and finish line will be marked on the floor 357 
2m in front and 2m behind both the even and uneven surface walkways, allowing 358 
participants to accelerate and decelerate outside the walkways [48]. Participants will 359 
be positioned at the start line and instructed to walk at their comfortable, self-360 
selected walking pace. Five walking trials will be completed on the even surface and 361 
5 trials on the uneven surface, each whilst barefoot, wearing standardised footwear 362 
only, and wearing two different shoe insoles (textured and smooth) within 363 
standardised footwear. The test sequence (footwear condition, surface) will be 364 
randomised. Spatiotemporal gait variables will be measured using the GAITRite® 365 
system (sampling rate 80Hz) when walking over the even surface, and using an 11-366 
camera Vicon® motion capture system (Vicon, 6 x MX13 and 5 x T40 cameras, 367 
giganet control box, with a MX Net and Mx Link), sampled at 200Hz, when walking 368 
over the uneven surface. Participants will have multiple reflective markers attached 369 
to their body, following the Vicon PlugIn Gait full body model. The Vicon system 370 
records the position of reflective markers placed at standardised anatomical sites on 371 
the upper and lower body and will be used to measure spatiotemporal gait variables 372 
and gait kinematics.  373 
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 374 
Balance  375 
Standing balance will be assessed to provide a measure of basic, unperturbed 376 
postural stability. Participants will stand on an AMTI force platform (sampling rate 377 
1000Hz), using a standardised foot position (heels placed 1/10th participants height 378 
apart and angled to 14° [51]), and arms hanging by their sides, for 30 seconds [52]. 379 
Double-limb standing tests will be performed on a firm and foam surface, with their 380 
eyes open and eyes closed. To prevent vestibular disruption when standing with 381 
eyes open, participants will be instructed to look straight ahead and focus on the 382 
middle of a black circular visual target (10cm diameter), mounted onto a board 383 
positioned 3 metres from the centre of the force platform, and adjusted to the eye 384 
level of each participant. Standing balance will be assessed whilst barefoot, wearing 385 
standardised footwear only, and when wearing two different shoe insoles (textured 386 
and smooth) within standardised footwear. The test sequence (footwear condition, 387 
surface, vision) will be randomly presented. Measures of baseline standing balance 388 
will include centre of pressure (CoP) path velocity, range and standard deviation of 389 
CoP movement in the anterior-posterior and mediolateral directions. 390 
 391 
Foot sensation and proprioception 392 
Somatosensory function, including light touch-pressure sensation, vibration sense, 393 
and two-point discrimination will be assessed. Semmes-Weinstein monofilaments 394 
(smallest [1.65] to largest [6.65]) will be used to determine light touch-pressure 395 
sensation at five locations on the foot: plantar surface of the great toe; first 396 
metatarsal head; fifth metatarsal head; heel; and dorsum of the foot between the first 397 
and second toes [53]. The monofilaments will be applied perpendicular to the skin for 398 
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1.5 seconds, and the participant will be required to indicate whether the fibre can be 399 
felt. The smallest monofilaments (1.65-4.08) will be applied three times 400 
consecutively, whilst larger ones (4.17-6.65) will be applied only once [15]. Duration 401 
of vibration sense will be measured using a 128-Hz frequency tuning fork at the first 402 
metatarsal head and medial malleoli of both feet [15]. The ability to distinguish 403 
between two light-touch stimuli (two-point discrimination) will be measured using an 404 
aesthesiometer applied to the skin at three foot regions: tip of the great toe; first to 405 
second metatarsal interspace, fifth metatarsal head. Each region will be touched with 406 
either one point or two points simultaneously in a random order, with approximately 2 407 
seconds between each application of the stimuli. Assessment will begin with the two 408 
stimuli at the maximum distance apart, and decrease until the participant can no 409 
longer differentiate the two points [15]. Foot position awareness will be assessed 410 
bilaterally using the ankle joint angle reproduction test [33]. The investigator will 411 
passively set the participant’s ankle joint to three pre-determined angles in 412 
plantarflexion and dorsiflexion directions, relative to a neutral foot position. A variable 413 
time and trajectory will be used when positioning the foot in order to eliminate 414 
extraneous cues and psychophysical processes. The participant will be asked to 415 
reposition the ankle joint at the target angle, by moving only the foot segment. 416 
Accuracy in joint positioning will be determined by measuring the difference between 417 
the target and actual angles using an internet-based goniometer [54]. This 418 
application has been shown to be a valid method for measuring joint angles and has 419 
a high level of inter- (ICC2,1=0.96 to >0.99) and intra- (ICC= all >0.99) rater reliability 420 
[54]. 421 
 422 
Post-intervention assessment 423 
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Gait, foot sensation and proprioception will be assessed within two weeks of the end 424 
of the 12-week intervention period, using the same procedures employed at 425 
baseline. A 12-week intervention period will provide maximal time to allow for the 426 
accrual of any sensory training effects and accumulation of meaningful changes in 427 
outcomes measures, in particular for participants with MS who show minimal gait 428 
disturbance at baseline and currently engage in an active lifestyle. This intervention 429 
period is consistent with previous randomised controlled trial intervention studies 430 
conducted in pwMS [11, 27, 28], and footwear intervention trials [55, 56]. This final 431 
point of assessment will: (i) quantify whether any immediate changes in gait, 432 
observed at baseline, have accrued over time, or if additional effects can be seen 433 
and; (ii) determine whether there are any alterations in the perception of foot 434 
sensation or proprioception, which may suggest the insoles have a sensory training 435 
effect. Participants will be asked to return their insole wear diaries and falls 436 
calendars at this time. Participants will also be asked to rate the level of comfort 437 
experienced when wearing the insoles by way of a series of 100mm visual analogue 438 
scales (VAS) used in previously published research [57].  439 
 440 
Data analysis 441 
All analyses will be conducted in a blinded manner, on an intention-to-treat basis, 442 
with the alpha set to 0.05. We will explore frequency distributions, percentages and 443 
calculate means and standard deviations for the outcome measures. Differences 444 
between intervention and control groups in spatiotemporal gait variables, gait 445 
kinematics, foot sensation or proprioception, over the intervention period will be 446 
explored using General Linear Models (repeated measures analysis of variance, 447 
ANCOVA), in a two group (smooth control insole; textured insole) x 3 phase 448 
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(Baseline assessment 1, Baseline assessment 2, Post-intervention) model. We will 449 
adjust for potential confounding variables (e.g. age, gender, disease duration) by 450 
using these as covariates. Non-parametric tests will be used where data is not 451 
normally distributed or violates the assumption of sphericity. Multiple regression 452 
modelling will be used to determine any relationships between foot sensation, 453 
proprioception and measures of gait performance. Data will be analysed using SPSS 454 
version 22 (SPSS Inc., Chicago, IL 60606, USA). 455 
 456 
Discussion 457 
Gait impairment is one of the most disabling and debilitating complaints reported by 458 
pwMS [5]. Deteriorating mobility observed in the early stages of disease [6-8] not 459 
only increases the risk of falling [1, 2], but frequently culminates in a complete loss of 460 
walking ability in the advanced stages [58]. The associated personal and societal 461 
burdens can have devastating implications for the individual, their families, and 462 
national health services. Physical rehabilitation strategies reported to improve gait in 463 
pwMS commonly involve short-term multi-component exercise programs [9-13]. 464 
Maintenance of walking stability is attributed to optimal sensorimotor function, 465 
however therapeutic management of gait impairments in pwMS, largely focuses on 466 
addressing motor problems and poor aerobic capacity, and to a lesser extent 467 
sensory training, which is commonly addressed purely by way of balance tasks 468 
under a variety of sensory conditions. Interventions targeting sensory impairments at 469 
a more local level, including foot sensation and lower limb proprioception, are not 470 
frequently incorporated. This is a crucial area to address as loss of foot sensation 471 
and impaired lower limb proprioception are strongly associated with standing 472 
balance and gait performance in pwMS [15, 19]. Therefore, the effectiveness of 473 
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current strategies for managing mobility in pwMS could be further enhanced by using 474 
a wider range of treatment techniques.  475 
 476 
Providing enhanced sensory input to the plantar surface of the feet has recently 477 
been considered a potential mechanism through which footwear interventions may 478 
improve gait [21, 22, 24, 59-63], by way of altering sensorimotor function. Underlying 479 
physiological mechanisms by which a textured insole may initiate changes in gait are 480 
suggested to include the provision of sufficient tactile stimulation to alter the rate of 481 
discharge from mechanoreceptors or firing patterns of populations of sensory 482 
afferents located in the feet. Textured shoe insoles appear to have the capacity to 483 
alter gait patterns, potentially improving gait stability in ageing, neurodegenerative 484 
and neuromuscular disease groups with known balance impairments. To date, 485 
exploratory studies report that wearing shoe insoles deigned to enhance plantar 486 
sensation can significantly increase single-limb support time [24], increase stride 487 
length and reduce double-limb support time [32] during walking in people with 488 
Parkinson’s disease. Similar conclusions are emerging for pwMS, with exploratory 489 
work observing beneficial alterations in spatiotemporal gait parameters [20], gait 490 
kinetics and kinematics [21]. 491 
 492 
This randomised controlled trial will use fundamental knowledge of sensory and 493 
motor function in MS to develop novel ways to improve gait by way of enhancing 494 
sensory information at the soles of the feet. Preliminary work in this clinical 495 
population [20] provides strong evidence of improvements in gait patterns when 496 
textured insoles were worn (as a single intervention) for two weeks. It is possible that 497 
the benefits of wearing textured insoles may accrue, and additional benefits may be 498 
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observed, over a longer period of time. Findings from this trial could have 499 
implications on the management of gait impairment in pwMS. The benefit for pwMS 500 
(and their families) is that this study may lead to the development of a new, 501 
evidence-based footwear intervention which is inexpensive, non-invasive, promotes 502 
self-management by the user, and has the capacity to enhance mobility and 503 
independent living. Furthermore, addressing problems with mobility, and 504 
subsequently quality of life, could have a major economic impact, through 505 
improvements in productivity or reducing working days lost. The benefit for health 506 
care professionals is that this study may generate vital evidence to inform the 507 
development of more effective, multi-faceted and multi-disciplinary rehabilitation 508 
programmes, which are tailored to address a greater range of MS-specific 509 
impairments that contribute to deteriorating gait. This could have major implications 510 
on current clinical guidelines and policy relating to physical rehabilitation strategies 511 
for pwMS. 512 
 513 
List of abbreviations 514 
ANCOVA: analysis of covariance; CoP: Centre of pressure; EDSS: Expanded 515 
Disability Severity Scale; EVA: ethyl vinyl acetate; ICC: intraclass correlation 516 
coefficient; ML: mediolateral; MMSE: Mini-mental state examination; MOS: Medical 517 
Outcomes Study; MS: Multiple Sclerosis; MSIS-29: Multiple Sclerosis Impact Scale; 518 
MS QoL-54: Multiple Sclerosis Quality of Life Instrument; MSWS-12: Multiple 519 
Sclerosis Walking Scale; pwMS: people with Multiple Sclerosis; SD: standard 520 
deviation; SPSS: Statistical Package for the Social Sciences VAS: visual analogue 521 
scale 522 
 523 
22 
 
Competing interests (non-financial) 524 
The textured insoles and smooth control insoles investigated in this study were 525 
supplied by Algeos PTY. Ltd. (Liverpool, UK). This company had no involvement in 526 
the conception or design of the study or preparation of this manuscript; and will not 527 
be involved in subsequent data acquisition, analysis or interpretation.  528 
 529 
Acknowledgments 530 
This project is funded by Multiple Sclerosis Research Australia. The funding body 531 
had no involvement in the conception or design of the study or preparation of this 532 
manuscript; and will not be involved in subsequent data acquisition, analysis or 533 
interpretation.  534 
 535 
Authors’ contributions 536 
AH conceived the idea for the study and took primary responsibility for drafting the 537 
manuscript. All authors obtained funding for the study, contributed to the design of 538 
the trial protocol, intervention, and outcome measures, and preparation of the 539 
manuscript. All authors have read and approved the final manuscript. 540 
 541 
 542 
 543 
 544 
 545 
 546 
 547 
 548 
23 
 
References 549 
1. Cattaneo D, De Nuzzo C, Fascia T, Macalli M, Pisoni I, Cardini R. Risks of 550 
falls in subjects with multiple sclerosis. Arch Phys Med Rehabil 2002;83:864-551 
7. 552 
2. Finlayson M, Peterson E, Cho C. Risk factors for falling among people aged 553 
45 to 90 years with multiple sclerosis. Arch Phys Med Rehabil. 2006;87:1274-554 
9. 555 
3. Matsuda P, Shumway-Cook A, Bamer A, Johnson SL, Amtmann D, Kraft GH. 556 
Falls in multiple sclerosis: incidence, causes, risk factors and health care 557 
provider response. PM&R. 2011;3:624-32. 558 
4. Scheinberg L, Holland N, LaRocca N. Multiple Sclerosis: earning a living. N Y 559 
State J Med. 1980;80:1395-400. 560 
5. Finlayson M. Concerns about the future among older adults with Multiple 561 
Sclerosis. Am J Occup Ther. 2004;58:54-63. 562 
6. Givon U, Zeilig G, Achiron A. Gait analysis in multiple sclerosis: 563 
Characterization of temporal-spatial parameters using GAITRite functional 564 
ambulation system. Gait Posture. 2009;29:138-42. 565 
7. Kalron A, Dvir Z, Achiron A. Walking while talking - Difficulties incurred during 566 
the initial stages of multiple sclerosis disease process. Gait Posture. 567 
2010;32:332-5. 568 
8. Martin C, Philips B, Kilpatrick T, Butzkueven H, Tubridy N, McDonald E et al. 569 
Gait and balance impairment in early multiple sclerosis in the absence of 570 
clinical disability. Mult Scler. 2006;12:620-8. 571 
9. Cattaneo D, Jonsdottir J, Zocchi M, Regola A. Effects of balance exercises on 572 
people with multiple sclerosis: a pilot study. Clin Rehabil. 2007;21:771-81. 573 
24 
 
10. Kasser SL, Jacobs JV, Ford M, Tourville TW. Effects of balance-specific 574 
exercises on balance, physical activity and quality of life in adults with multiple 575 
sclerosis: a pilot investigation. Disabil Rehabil. 2015;1-12. 576 
11. Learmonth YC, Paul L, McFadyen AK, Marshall-McKenna R, Mattison P, 577 
Miller L et al. The effects of a 12-week leisure centre-based, group exercise 578 
intervention for peopler moderately affected with multiple sclerosis: a 579 
randomized controlled pilot study. Clin Rehabil. 2012;26:579-93. 580 
12. Sangelaji B, Nabavi SM, Estebsari F, Banshi MR, Rashidian H, Jamshidi E et 581 
al. Effect of Combination Exercise Therapy on Walking Distance, Postural 582 
Balance, Fatigue and Quality of Life in Multiple Sclerosis Patients: A Clinical 583 
Trial Study. Iran Red Crescent Med J. 2014;16:e17173. 584 
13. Vore ME, Elgelid S, Bolger S, Parsons C, Quashnoc R, Raymor J. Impact of a 585 
10-Week Individualized Exercise Program on Physical Function and Fatigue 586 
of People with Multiple Sclerosis: A Pilot Study. Int J MS Care. 2011;13:121-6. 587 
14. Cattaneo D, Jonsdottir J. Sensory impairments in quiet standing in subjects 588 
with multiple sclerosis. Mult Scler. 2009;15:59-67. 589 
15. Citaker S, Gunduz AG, Guclu MB, Nazliel B, Irkec C, Kaya D. Relationship 590 
between foot sensation and standing balance in patients with multiple 591 
sclerosis. Gait Posture. 2011;34:275-8. 592 
16. Frzovic D, Morris ME, Vowels L. Clinical tests of standing balance: 593 
performance of persons with multiple sclerosis. Arch Phys Med Rehabil 594 
2000;81:215-21. 595 
17. Rougier P, Thoumie P, Cantalloube S, Lamotte D. What compensatory motor 596 
strategies do patients with multiple sclerosis develop for balance control? Rev 597 
Neurol (Paris) 2007;163:1054-64. 598 
25 
 
18. Soyuer F, Mirza M, Erkorkmaz U. Balance performance in three forms of 599 
multiple sclerosis. Neurol Res. 2006;28:555-62. 600 
19. Thoumie P, Mevellec E. Relation between walking speed and muscle strength 601 
is affected by somatosensory loss in multiple sclerosis. J Neurol Neurosurg 602 
Psychiatry. 2002;73:313-5. 603 
20. Dixon J, Hatton AL, Robinson J, Gamesby-Iyayi H, Hodgson D, Rome K et al. 604 
Effect of textured insoles on balance and gait in people with multiple sclerosis: 605 
an exploratory trial. Physiotherapy. 2014;100:142-9. 606 
21. Kelleher KJ, Spence WD, Solomonidis S, Apatsidis D. The effect of textured 607 
insoles on gait patterns of people with multiple sclerosis. Gait Posture 608 
2010;32:67-71. 609 
22. Ramdharry GM, Marsden JF, Day BL, Thompson AJ. De-stabilizing and 610 
training effects of foot orthoses in multiple sclerosis. Mult Scler. 2006;12:219-611 
26. 612 
23. Hatton AL, Dixon J, Rome K, Newton JL, Martin DJ. Altering gait by way of 613 
stimulation of the plantar surface of the foot: the immediate effect of wearing 614 
textured insoles in older fallers. J Foot Ankle Res. 2012;5:11. 615 
24. Jenkins ME, Almeida QJ, Spaulding SJ, van Oostveen RB, Holmes JD, 616 
Johnson AM et al. Plantar cutaneous sensory stimulation improves single-limb 617 
support time and EMG activation patterns among individuals with Parkinson's 618 
disease. Parkinsonism Relat Disord. 2009;15:697-702. 619 
25. Kalron A, Pasitselsky D, Greenberg-Abrahami M, Achiron A. Do textured 620 
insoles affect postural control and spatiotemporal parameters of gait and 621 
plantar sensation in people with Multiple Sclerosis? PM&R. 2015;7:17-25. 622 
26 
 
26. Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated 623 
guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c323. 624 
27. Dalgas U, Stenager E, Jakobsen J, Petersen T, Hansen HJ, Knudsen C et al. 625 
Resistance training improves muscle strength and functional capacity in 626 
multiple sclerosis. Neurology. 2009;73:1478-84. 627 
28. Collett J, Dawes H, Meaney A, Sackley C, Barker K, Wade D et al. Exercise 628 
for multiple sclerosis: a single-blind randomized trial comparing three exercise 629 
intensities. Mult Scler. 2011;17:594-603. 630 
29. Hohol MJ, Orav EJ, Weiner HL. Disease steps in multiple sclerosis: a simple 631 
approach to evaluate disease progression. Neurology. 1995;45:251-5. 632 
30. Folstein M, Folstein S, McHugh P. "Mini-mental state". A practical method for 633 
grading the cognitive state of patients for the clinician. J Psychiatr Res 634 
1975;12:189-98. 635 
31. Wilson ML, Rome K, Hodgson D, Ball P. Effect of textured foot orthotics on 636 
static and dynamic postural stability in middle-aged females. Gait Posture. 637 
2008;27:36-42. 638 
32. Qiu F, Cole MH, Davids KW, Hennig EM, Silburn PA, Netscher H et al. Effects 639 
of textured insoles on balance in people with Parkinson's disease. PLoS One. 640 
2013;8:e83309. 641 
33. Riskowski JL, Mikesky AE, Bahamonde RE, Alvey TV, Burr DB. 642 
Proprioception, gait kinematics, and rate of loading during walking: Are they 643 
related? J Musculoskelet Neuronal Interact 2005;5:379-87. 644 
34. Lamb SE, Jørstad-Stein EC, Hauer K, Becker C. Development of a common 645 
outcome data set for fall injury prevention trials: the Prevention of Falls 646 
Network Europe consensus. J Am Geriatr Soc. 2005;53:1618-22. 647 
27 
 
35. Hohol MJ, Orav EJ, Weiner HL. Disease steps in multiple sclerosis: a 648 
longitudinal study comparing Disease Steps and EDSS to evaluate disease 649 
progression. Mult Scler. 1999;5:349-54. 650 
36. Tardieu G, Shentoub S, Delarue R. A la recherche d'une technique de mesure 651 
de la spasticite. Rev Neurol (Paris). 1954;91:143-4. 652 
37. Schmahmann JD, Gardner R, MacMore J, Vangel MG. Development of a 653 
Brief Ataxia Rating Scale (BARS) based on a modified form of the ICARS. 654 
Movement Disord. 2009;24:1820-8. 655 
38. Hobart J, Lamping D, Fitzpatrick R, Riazi A, Thompson A. The Multiple 656 
Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. 657 
Brain. 2001;124:962-73. 658 
39. Hobart JC, Riazi A, Lamping DL, Fitzpatrick R, Thompson AJ. Measuring the 659 
impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12). 660 
Neurology. 2003;60:31-6. 661 
40. Vickrey BG, Hays RD, Harooni R, Myers LW, Ellison GW. A health-related 662 
quality of life measure for multiple sclerosis. Qual Life Res. 1995;4:187-206. 663 
41. Fisk JD, Pontefract A, Ritvo PG, Archibald CJ, Murray TJ. The impact of 664 
fatigue on patients with multiple sclerosis. Can J Neurol Sci. 1992;21:9-14. 665 
42. Archibald CJ, McGrath PJ, Ritvo PG, Fisk JD, Bhan V, Maxner CE et al. Pain 666 
prevalence, severity and impact in a clinical sample of multiple sclerosis 667 
patients. Pain. 1994;58:89-93. 668 
43. Sullivan JJL, Edgley K, Dehoux E. A survey of multiple sclerosis. Part 1: 669 
perceived cognitive problems and compensatory strategy use. Can J Rehabil. 670 
1990;4:99-105. 671 
28 
 
44. Yardley L, Beyer N, Hauer K, Kempen G, Piot-Ziegler C, Todd C. 672 
Development and initial validation of the Falls Efficacy Scale-International. 673 
Age Ageing. 2005;34:614-9. 674 
45. Snook EM, Motl RW, Gliottoni RC. The effect of walking mobility on the 675 
measurement of physical activity using accelerometry in multiple sclerosis. 676 
Clin Rehabil 2009;23:248-58. 677 
46. Weikert M, Motl RW, Suh Y, McAuley E, Wynn D. Accelerometry in persons 678 
with multiple sclerosis: measurement of physical activity or walking mobility? J 679 
Neurol Sci. 2010;290:6-11. 680 
47. Goldman MD, Motl RW, Rudick RA. Possible clinical outcome measures for 681 
clinical trials in patients with multiple sclerosis. Ther Adv Neurol Disord. 682 
2010;3:229-39. 683 
48. Batey P, Rome K, Finn P, Hanchard N. Assessing reliability of measurement 684 
of gait velocity. Physiotherapy. 2003;89:313-7. 685 
49. Menz HB, Latt MD, Tiedemann A, Mun San Kwan M, Lord SR. Reliability of 686 
the GAITRite walkway system for the quantification of temporo-spatial 687 
parameters of gait in young and older people. Gait Posture. 2004;20:20-5. 688 
50. Menant JC, Steele JR, Menz HB, Munro BJ, Lord SR. Effects of walking 689 
surfaces and footwear on temporo-spatial gait parameters in young and older 690 
people. Gait Posture. 2009;29:392-7. 691 
51. McIlroy WE, Maki BE. Preferred placement of the feet during quiet stance: 692 
development of a standardized foot placement for balance testing. Clin 693 
Biomech. 1997;12:66-70. 694 
52. Hatton AL, Dixon J, Rome K, Martin D. Standing on textured surfaces: effects 695 
on standing balance in healthy older adults. Age Ageing. 2011;40:363-8. 696 
29 
 
53. Armstrong DG, Lavery LA, Vela SA, Quebedeaux TL, Fleischli JG. Choosing 697 
a practical screening instrument to identify patients at risk for diabetic foot 698 
ulceration. Arch Intern Med. 1998;158:289-92. 699 
54. Russell TG, Jull GA, Wootton R. Can the Internet be used as a medium to 700 
evaluate knee angle? Manual Ther. 2003;8:242-6. 701 
55. Chalmers AC, Busby C, Goyert J, Porter B, Schulzer M. Metatarsalgia and 702 
rheumatoid arthritis: a randomized, single-blind, sequential trial comprising 2 703 
types of foot orthoses and supportive shoes. J Rheumatol 2000;27:1632-7. 704 
56. Hinman RS, Payne C, Metcalf BR, Wrigley TV, Bennell KL. Lateral wedges in 705 
knee osteoarthritis: What are their immediate clinical and biomechanical 706 
effects and can these predict a three-month clinical outcome. Arthritis Care 707 
Res. 2008;59:408-15. 708 
57. Mills K, Blanch P, Vicenzino B. Identifying clinically meaningful tools for 709 
measuring comfort perception of footwear. Med Sci Sports Exerc. 710 
2010;42:1966-71. 711 
58. Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J 712 
et al. The natural history of multiple sclerosis: A geographically based study 1. 713 
Clinical course and disability. Brain. 1989;112:133-46. 714 
59. Galica AM, Kang HG, Priplata AA, D'Andrea SE, Starobinets OV, Sorond FA 715 
et al. Subsensory vibrations to the feet reduce gait variability in elderly fallers. 716 
Gait Posture. 2009;30:383-7. 717 
60. Maki BE, Perry SD, Norrie RG, McIlroy WE. Effect of facilitation of sensation 718 
from plantar foot-surface boundaries on postural stabilization in young and 719 
older adults. J Gerontol A Biol Sci Med Sci 1999;54A:M281-7. 720 
30 
 
61. Novak P, Novak V. Effect of step-synchronized vibration stimulation of soles 721 
on gait in Parkinson's disease: a pilot study. J Neuroeng Rehabil 2006;3:9. 722 
62. Nurse MA, Hulliger M, Wakeling JM, Nigg BM, Stefanyshyn DJ. Changing the 723 
texture of footwear can alter gait patterns. J Electromyogr Kinesiol. 724 
2005;15:496-506. 725 
63. Perry SD, Radtke A, McIlroy WE, Fernie GR, Maki BE. Efficacy and 726 
effectiveness of a balance-enhancing insole. J Gerontol A Biol Sci Med Sci. 727 
2008;63A:595-602. 728 
 729 
 730 
Figure 1: Trial Design 731 
  
 
 
 
 
 
 
 
  
Clinical screening examination 
Eligible participants recruited and consented 
Initial contact through Multiple Sclerosis Queensland; Multiple 
Sclerosis community and health care services across the Brisbane, 
Gold Coast, Logan regions; local media 
Assessed for eligibility via telephone screening 
Eligible participants invited for clinical screening examination 
En
ro
lm
en
t 
Habitual activity monitoring (7 consecutive days) 
Spatiotemporal gait variables & gait kinematics 
 Walking over even and uneven ground (2 surfaces, 4 footwear conditions) 
Sensory measures 
 Foot sensation: Light touch-pressure, vibration sense, two-point discrimination 
 Proprioception: Ankle joint position sense  
Baseline assessments  
 Demographics, medical history, self-report questionnaires addressing quality of 
life, impact of symptoms, perceived disability, falls 
 Balance: Quiet standing (2 surfaces, 2 visual conditions, 4 footwear conditions)  
  
Baseline assessment 1 (Week 0) 
Baseline assessment 2 (Week 4) 
Randomisation (N=176) 
Spatiotemporal gait variables & gait kinematics 
Sensory Measures: Foot sensation, Proprioception  
Textured insole 
(N=88) 
Spatiotemporal gait variables & gait kinematics 
Sensory measures: Foot sensation, Proprioception  
Insole wear diaries & falls calendars 
 
 Withdrawal 
 Exacerbation of Multiple Sclerosis symptoms 
lasting >24hrs 
 Discontinued intervention 
 Lost to follow-up 
 Deceased 
Post-intervention assessment (Week 16) 
Excluded 
 Not meeting criteria 
 Declined to participate 
 Deceased 
 Other 
 Withdrawal 
 Exacerbation of Multiple 
Sclerosis symptoms lasting 
>24hrs 
 Lost to follow-up 
 Deceased 
 Other 
Analysed  
(Excluded from analysis) 
A
llo
ca
ti
o
n
  
Fo
llo
w
-u
p
 
A
n
al
ys
is
 
Smooth insole 
(N=88) 
Spatiotemporal gait variables & gait kinematics 
Sensory measures: Foot sensation, Proprioception  
Insole wear diaries & falls calendars 
 
 Withdrawal 
 Exacerbation of Multiple Sclerosis symptoms 
lasting >24hrs 
 Discontinued intervention 
 Lost to follow-up 
 Deceased 
Post-intervention assessment (Week 16) 
Analysed  
(Excluded from analysis) 
 
12-week intervention period 
